Located at the Valld’Hebron Research Institute (VHIR) in Barcelona, U20 In vivo Experimental Platform has three different sections, a Molecular Imaging section for in vivo, ex vivo and in vitro imaging studies (fluorescence, bioluminescence and X-rays), a preclinical animal model section and a preclinical histology section. All three sections are included within the Functional Validation & Preclinical Research (FVPR) of CIBBIM-Nanomedicine.
This unit is leadedby Dr. Ibane Abasolo (Head of FVPR) and supervised by the directorof CIBBIM-Nanomedicine, Dr. Simó Schwartz Jr. Its mission is to offer products and services for the preclinical proof-of-concept validation of therapeutic compounds and biomarkers with potential clinical applications. One of the distinguishing features of this unit is that basic preclinical studies including toxicology, histopathology and efficacy treatments are complemented with non-invasive optical imaging technologies. In vivo bioluminescence and fluorescence imaging allows monitoring of living mice longitudinally, offering real time insight into treatment efficacy, whole-body biodistribution and target mechanisms. Although in Spain there are other institutions with similar equipment, this is the only case in which imaging services can be combined with specifically devoted animal models.
FOR THOSE SERVICES IDENTIFIED AS OUTSTANDING, AT LEAST 20% OF THEIR CAPACITY IS OPEN UNDER COMPETITIVE ACCESS. SEE ANNEX 1 OF ACCESS PROTOCOL FOR DETAILS ON % OF OPENNESS FOR EACH SERVICE
The new magazine “Precision Nanomedicine” in its online version, is about to be issued. Dr. Simón Schwartz Jr, Scientific Director of NANBIOSIS U20 In Vivo Experimental Platform, is one of only two Spanish researchers who are part of the editorial board of the journal. The rest of publishers belong to the United States, Australia, Japan and Europe Precision Nanomedicine is a publication promoted by the European Society of Nanomedicine (ESNAM for its acronym in English), the European Nanomedicine Foundation and the Conference of Clinical Nanomedicine (Clinamen). It was born with the aim of bringing together the most important opinion leaders in this field, disseminating t[...]
Simó Shwartz, Scientific Director of NANBIOSIS U20 In vivo Experimental Platform, has recently published an interesting article “Efficient EFGR mediated siRNA delivery to breast cancer cells by Cetuximab functionalized Pluronic® F127/Gelatin” issued by Chemical Engineering Journal. The research group of Dr Schwartz has managed to create a micelle formed by a combination of polymers and gelatin that allows to transport effectively large quantities of both nucleic acids and drugs inside. The system also leads to the periphery a series of carboxylic groups that allow anchoring in a very easy way any type of directing molecule such as for example a peptide or[...]
Smart-4-Fabry is a project coordinated by CIBER-BBN, funded by the European Commission within the Horizon 2020 Research and Innovation program with € 5.8 M for 4 years, which aims to develop a new nanomedicine for the treatment of the Fabry rare disease. Fabry disease is a rare disease belonging to the group of lysosomal storage disorders, with a global incidence of 1:5,000 – 1:10,000, representing a priority health problem at European level. The European project “Smart-4-Fabry”, is coordinated by CIBER-BBN, specifically by NANOMOL group at ICMAB-CSIC (Dr. Nora Ventosa) and the Biomaterial Processing and Nanostructuring Unit (U6) of ICTS “NANBIOSIS”, and it[...]
The Area of Functional Validation & Preclinical Research of CIBBIM-Nanomedicine has recently obtained the ISO 9001:2008 certification of Quality Management System. Functional Validation & Preclinical Research (FVPR), led by Dr. Ibane Abasolo, Scientific Coordinator of Unit 20 of NANBIOSIS “In Vivo experimental Platform“, was created in 2007 as part of the CIBBIM-Nanomedicine’s technological offer. The objective of FVPR is to provide services to the different research groups of the mother institutions (VHIR and CIBER), as well as to external companies or groups, to evaluate the effectiveness and toxicity of new therapeutic agents or targets, whether they are nanotechnology-based or not. To this end, it has[...]
The national consortium led by the research group of Addressing and Drug Release CIBBIM – Nanomedicine of the Vall d’Hebron Research Institute (VHIR) and led by Dr. Ibane Abasolo, Scientific Coordinataror of Unit 20 of NANBIOSIS, has shown improvement in the effectiveness and specificity of targeted therapy against cancer through the use of polyurethane-polyurea nanocapsules (PUUa), a nanoparticle with a proven targeted release, very useful for drugs with a high level of toxicity and low specificity of distribution. This nanoparticle has been developed by the research section of the Catalan company EcopolTech and Unit 20 of ICTS Nanbiosis has participated in[...]
Last 13 and 14 of November, CIBER-BBN has celebrated its 11th Annual Conference in Hotel Santemar in Santander. In this conference there was a poster session with the participation of the following Units of NANBIOSIS. Special mention deserves Unit 1 with Neus Ferrer as Director and Paolo Saccardo as Coordinator (in the picture): Posters: U1. Protein Production Platform (PPP): Engineering protein complexes as nano- or micro-structured vehicles or drugs for human and veterinary medicine. Ugutz Unzueta, Naroa Serna, Laura Sánchez-García, José Vicente Carratalá, Olivia Cano-Garrido, Mercedes Márquez, Paolo Saccardo, Rosa Mendoza, Raquel Díaz, Héctor, López-Laguna, Julieta Sánchez, Anna Obando, Amanda Muñoz, Andrés Cisneros, Eric Voltà, Aida Carreño, José[...]
The second Summer School in Nanomedicine coordinated by Simó Schwartz, Scientific Director of NANBIOSIS unit 20, was held at Vall d’Hebron hospital on 28 and 29 September. Dr. Schwartz has been the president of the European Society for Nanomedicine (ESNAM), a European scientific society focused on the clinical application of nanomedicine. From this society tasks are carried out to promote the research and the use of nanomedicine in the health sector, as well as to facilitate the exchange of knowledge in this area at European level among all the actors involved, Academy, industry and entities regulators. CIBER-BBN, partner of NANBIOSIS,[...]
NANBIOSIS-U20 Scientific Director, Simó Schwartz, speaks about Nanomedicine in an interview publish in http://www.quimicaysociedad.org. NANBIOSIS is an Singular Scientific Technological Infrastructure (ICTS) that provides a complete service for the production and characterization of nanomaterials, biomaterials and systems in biomedicine, including the design and production of biomaterials and nanomaterials and their nanoconjugates, and the characterization of these bio-/nanomaterials, tissues and medicals devices from a physic-chemical, functional, toxicological and biological (including preclinical validation) point of view, focused also on biomedical applications such as: IVDs, biosensors, regenerative medicine, drug delivery, therapeutic agents or MRI contrast agents and medical devices. Question: First of all,[...]